Shiga toxin (STX) is a ribosome-inactivating cytotoxin produced by ShigeUa dysenteriae serotype 1. The enzymatic domain of the STX A polypeptide has been defined by introducing amino-and carboxy-terminal deletions in the polypeptide and assessing activity in a cell-free translation system. Three recombinant forms of StxA which possess enzymatic activity were genetically fused to a 165-amino-acid polypeptide derived from CD4, the cellular receptor for human immunodeficiency virus type 1 (HIV-1). This strategy eliminated the STX receptor-binding subunit and directed the hybrid toxins to cells expressing the HIV-1 surface glycoprotein gpl20. A bacterial lysate containing these toxin chimeras killed the HIV-1-infected T-cell line 8E5 but was not cytotoxic toward the uninfected parental cell line A3.01. This cytotoxic activity was specifically inhibited by monoclonal antibodies which block the interaction between CD4 and gpl20. These StxA-CD4 hybrids add to the repertoire of recombinant fusion proteins which possess the capacity to selectively kill HIV-1-infected T cells.
gpl20. A bacterial lysate containing these toxin chimeras killed the HIV-1-infected T-cell line 8E5 but was not cytotoxic toward the uninfected parental cell line A3.01. This cytotoxic activity was specifically inhibited by monoclonal antibodies which block the interaction between CD4 and gpl20. These StxA-CD4 hybrids add to the repertoire of recombinant fusion proteins which possess the capacity to selectively kill HIV-1-infected T cells.
Shiga toxin (STX), which is produced by Shigella dysenteriae serotype 1, is composed of a single copy of an enzymatic A subunit (31 kDa) noncovalently linked to a ring-shaped pentamer of receptor-binding B subunits (7 kDa) . The B subunits mediate toxin binding to a glycolipid receptor on mammalian cells (17) . A single disulfide bond links the enzymatically active STX Al subunit (27 kDa) to the C-terminal A2 polypeptide which penetrates the pore of the STX B pentamer (12) .
STX is a member of the family of ribosome-inactivating proteins, which includes the Shiga-like toxins produced by Escherichia coli (14) and a variety of proteins produced by plants (27) . This family of single-site rRNA N-glycosidases inhibit protein synthesis in eucaryotic or procaryotic cells by releasing an adenine residue from the highly conserved aminoacyl-tRNA-binding site which exists on the large subunit of ribosomes (7) . Mutational analysis has been used to identify the StxA residues which are responsible for binding to and depurinating 28S rRNA. Recently, the minimum domain required for enzymatic activity was identified by introducing Nand C-terminal deletions in the STX A subunit (11) . In this study, enzymatic polypeptides derived from StxA were fused to the N terminus of CD4, the T-lymphocyte receptor for human immunodeficiency virus type 1 (HIV-1).
CD4 is an immunoglobulin-like polypeptide with four extracellular domains, a transmembrane domain, and a cytoplasmic domain (6) . Berger et al. (2) showed that the N-terminal 180 amino acids of CD4 bind to the external domains of the HIV-1 envelope glycoprotein gpl20. This interaction between gpl20 and CD4 facilitates the binding and penetration of viral particles into T lymphocytes. In addition, this interaction is essential for syncytium formation, which is required for cellcell spread of the virus. In this study, we have constructed gene fusions which encode truncated, enzymatically active forms of the STX A polypeptide fused to the gpl20-binding domain of CD4. The cytotoxicity of these fusion proteins was assessed by using HIV-1-infected human cell lines.
MATERIALS AND METHODS
Construction of recombinant plasmids. Sequences encoding the 165-amino-acid gpl20-binding region of CD4 carried on a 495-bp RsaI-StuI fragment (19) were fused in frame to truncated forms of the STX A polypeptide by ligation to an NruI site in the stxA gene (Fig. 1) . The recombinant plasmid carrying the human CD4 cDNA (pT4B) was supplied by Dan Littman (University of California, San Francisco). Four chimeric proteins with the StxA subunit at the amino terminus and the CD4 polypeptide at the carboxyl terminus were encoded by the plasmids designated pFUS40-CD4, pFUS60-CD4, pFUS80-CD4, and pJH460 in Table 1 . The recombinant plasmids were carried by E. coli HB101 (3) . Truncated forms of the STX A polypeptide expressed by pJH460, pFUS60, and pFUS80 were previously shown to express enzymatic activity by using a cell-free translation assay while the A polypeptide encoded by pFUS40 was not enzymatically active (11) .
While the C termini of all StxA-CD4 fusion proteins were composed of CD4 residues 19 to 183, the StxA content for each of the recombinant proteins differed (Table 1 and Fig. 1 ). Plasmid pJH460 encoded 247 N-terminal residues of StxA fused to the 165-amino-acid CD4 polypeptide and has been designated StxA247-CD4. The STX A polypeptides encoded by pFUS60-CD4, pFUS80-CD4, and pFUS40-CD4 were pro- Measurement of enzymatic activity. The A subunit of STX is an N-glycosidase which depurinates the 28S rRNA component of the 60S ribosomal subunit (7) . The enzymatic activities of the wild-type StxA encoded by the recombinant plasmid pNAS10 (28) and the truncated STX A polypeptides encoded by pFUS40-CD4, pFUS60-CD4, and pFUS80-CD4 were determined as previously described (11) by using a rabbit reticulocyte lysate translation assay and the luciferase gene mRNA (Promega, Madison, Wis.). Enzymatic activity was determined as a reduction in luciferase production and expressed as a percentage of StxA activity (Table 1) (10) and protein A as previously described (15) .
Extraction of StxA-CD4 hybrid toxins by sonication. The
StxA-CD4 hybrid toxins were extracted from E. coli by soni- (pFUS80-CD4), HB101(pFUS60-CD4), and HB101(pFUS40-CD4) were concentrated 10-fold in 3 ml of the culture supernatant and sonicated on ice for 3 min by using a microtip at the full-power setting. Sonic lysates were clarified by centrifugation at 10,000 x g for 10 min and sterilized by filtration. The protein concentration of the crude extracts was measured spectrophotometrically for each sample by using a protein assay kit (Bio-Rad Laboratories, Richmond, Calif.).
Assessment of cytotoxicity by trypan blue exclusion. The cytotoxic activity of the fusion proteins StxA247-CD4, StxA202-CD4, and StxA172-CD4 was determined by trypan blue dye exclusion with the human T-cell line 8E5, which harbors an integrated defective genome of HIV-1 (9) . The parental noninfected cell line A3.01 (8) Blocking studies. Two different MAbs were used to specifically inhibit cytotoxicity. MAb 0.5,, which has a high affinity for HIV-1 gpl20 (20) , was used to block the binding of the toxin chimeras to 8E5 cells. Purified mouse anti-human CD4 (Pharmingen) was used to block the CD4-gpl20 interaction. MAb 13C4, which blocks binding of the STX B subunit to its glycolipid receptor (29) , was used as a negative control. The isotype of all of the MAbs used in this study was immunoglobulin Gl, kappa chain. The capacity of the STX A polypeptides encoded by pFUS40, pFUS60, and pFUS80 to inhibit protein synthesis has been previously assessed by using a cell-free translation system (11) . Fusion of the STX A polypeptides encoded by pFUS60 (StxA202) and pFUS80 (StxA172) to the gpI20-binding domain of CD4 did not reduce this enzymatic activity. The enzymatic activities of StxA202-CD4 and StxA172-CD4 were 83 and 57%, respectively, compared with that of full-length StxA ( Table 1) . The level of enzymatic activity expressed by HB101(pJH460), which encoded a fusion between residues 1 to 247 of the 293-amino-acid STX A subunit and CD4, was essentially equivalent to that of full-length StxA. Because the A polypeptide encoded by pFUS40-CD4 (amino acids 79 to 247) lacked a critical active site residue at position 77 (5), it was not enzymatically active in the assay (Table 1) . Therefore, the hybrid toxin encoded by pFUS40-CD4 (StxA168-CD4) was used as a negative control in the cytotoxicity assays.
Cytotoxicity to 8E5 cells. The human T-cell lines A3.01 and its derivative 8E5, which harbors an integrated defective HIV-1 genome, were treated with sonic extracts containing the StxA247-CD4, StxA202-CD4, and StxA172-CD4 fusion proteins. The number of viable cells was measured by using the trypan blue exclusion assay.
Parental cell line A3.01 was not susceptible to the toxin chimeras encoded by any of these StxA-CD4 recombinant plasmids (Fig. 2) . However, StxA247-CD4, StxA202-CD4, and StxA172-CD4 were cytotoxic to the gpl20-expressing T-cell line 8E5 (Fig. 3) . StxA202-CD4 caused a 90% reduction in viable cell counts compared with the PBS-treated control.
Sonic extracts of E. coli HBlO1(pNAS10), which encodes intact STX (28) , had no significant effect on the 8E5 cells (Fig. 3) .
The cytotoxic effect of the toxin chimeras on 8E5 cells was also quantified by using the MTT assay (Fig. 4) . The results of treating 8E5 cells with the StxA-CD4 preparations and measuring oxidative metabolism by using MTT were consistent with those obtained by using trypan blue exclusion. Toxin chimeras StxA172-CD4, StxA202-CD4, and StxA247-CD4 caused significant reductions in the number of viable 8E5 cells. As with the trypan blue staining experiment, StxA202-CD4 was the most cytotoxic hybrid, causing a 10-fold reduction in viable 8E5 cells; and STX did not significantly reduce the number of cells (Fig. 4) hybrid toxins (Fig. 1) , StxA168-CD4 was only slightly toxic to 8E5 cells (Fig. 4) because the 168-amino-acid StxA polypeptide was not enzymatically active (Table 1) .
Infectious cell center assay. Results of the infectious cell center assay revealed that the toxin chimeras prevented the spread of HIV-1 from the infected T-cell line A3.01 to HeLa T4+ cells. A3.01 cells were infected with HIV-1 and treated with PBS or sonic extracts of E. coli encoding StxA247-CD4, StxA202-CD4, and StxA172-CD4. The toxin-treated, infected A3.01 cells were cocultivated with a HeLa T4+ cell monolayer for 4 days to permit cell-cell transmission of the virus. The number of infected cells was assessed by immunostaining by using an HIV-1 polyclonal serum. (Fig. 3 ) and MTT assay (Fig. 4) results, which showed that the StxA202-CD4 hybrid had the highest level of cytotoxicity among the four fusion proteins.
Cytotoxin neutralization. Cell surface gpl20 was blocked by treating 8E5 cells with the MAb 0.5p (20) prior to toxin exposure. In addition, the hybrid toxin extracts were incubated with a mouse anti-human CD4 MAb (Pharmingen) to block the interaction between CD4 and gp120. The anti-StxB MAb 13C4 (29) was used as a negative control in the neutralization experiments. The MAbs to gpl20 and CD4 significantly neutralized the cytotoxic activity of fusion proteins StxA247-CD4, StxA202-CD4, and StxA172-CD4 toward 8E5 cells (Table 2) . Cytotoxicity levels for StxA247-CD4 and StxA202-CD4 decreased at least 10-fold following treatment of the 8E5 cells with the MAbs to gpl20 or following preincubation of the hybrid toxins with the anti-CD4 MAb. StxA172-CD4 cytotoxicity was de- (Table 2) . DISCUSSION Following the discovery that the human T-cell marker CD4 is the receptor for HIV-1 (25) , several investigators constructed hybrid toxins which specifically kill cells which are infected with the virus and express gpl20. The A chain of ricin, a 28S rRNA N-glycosidase produced by castor beans, was targeted to HIV-1-infected cells by chemical coupling to CD4 (30) . In addition, the enzymatic domains of two bacterial toxins, Pseudomonas exotoxin A and diphtheria toxin, were fused to the gpl20-binding domain of CD4 by using recombinant DNA techniques (1, 4) . In this study, a bacterial toxin which is an enzymatic analog of ricin was genetically fused to recombinant CD4 and used to kill HIV-1-infected T cells. Sequences chosen for construction of the StxA-CD4 hybrid toxins were previously shown to encode the minimum domain of the A polypeptide which is required for enzymatic activity (11) and the variable-like domain of CD4 which binds to gpl20 (2, 19) . The three fusion proteins StxA247-CD4, StxA202-CD4, and StxA172-CD4, which contained decreasing lengths of the enzymatic domain of StxA, were constructed to enhance toxin entry and translocation by reducing the size of the chimeras. StxA247-CD4, which was the most enzymatically active of the hybrid toxins, was less cytotoxic than StxA202-CD4, suggesting that the uptake and translocation efficiency of the larger protein were reduced because of size. However, deletion of an additional 30 residues caused corresponding reductions in the cytotoxic and enzymatic activities of the smallest chimera, StxA172-CD4. It will be necessary to purify the StxA-CD4 fusion proteins in future studies to assess the specific activities of these toxin chimeras.
Although the lengths of the enzymatic portions of the StxA-CD4 fusions were varied to improve activity, the same 165-amino-acid CD4 polypeptide was used for all the hybrid toxins. The capacity of the StxA-CD4 hybrids to selectively kill HIV-1-infected T cells, coupled with the neutralization assays using the MAbs to CD4 and gpl20, indicated that these fusion proteins were routed inside the cell via CD4 and gpl20 interaction. However, as with all the toxin-CD4 chimeras, the mechanism for internalization and translocation of the bacterial or plant enzyme into the cytosol following the binding of CD4 to gpl20 is unknown.
Entry of HIV-1 into susceptible cells expressing cell surface CD4 has been studied extensively. Maddon et al. (18) suggested that binding of HIV-1 gpl20 to CD4 triggers uptake of the virus by receptor-mediated endocytosis. In contrast, Stein and coworkers (26) supported a mechanism whereby fusion of the HIV-1 envelope and cell membrane results in the penetration of HIV-1 into CD4+ cells. Because there is no possibility for membrane fusion with the StxA-CD4 chimeras, it seems more likely that these hybrid toxins enter by a mechanism which is analogous to receptor-mediated endocytosis. This supposition is supported by the established mechanism for internalization of STX. Binding of the STX B subunits to the glycolipid receptor induces redistribution of the receptors into coated pits and internalization of the toxin-glycolipid complex by receptor-mediated endocytosis (24) . STX escapes from the endosome and translocates to the ribosomes where it inhibits protein synthesis (23) . Although it is unlikely that the hybrid toxins gain entry into gpl20-expressing cells through coated VOL. 62, 1994 on October 14, 2017 by guest http://iai.asm.org/ Downloaded from pits, many membrane-associated viral glycoproteins cycle between the cell surface and the endosomal compartment (13) . Therefore, gpl20 may provide a productive route for the chimeric proteins to penetrate HIV-1-infected cells through this cycling process.
The StxA-CD4 fusion proteins increase the repertoire of hybrid toxins which specifically kill HIV-1-infected cells although they are ostensibly different from the other chimeras because of the enzymatic mode of action and the method of construction. Collectively, these chimeras may be used as molecular tools to provide insight into the interaction between CD4 and the glycoproteins of HIV-1, as well as the process of gpl20 cycling. In addition, the StxA-CD4 hybrids may be used to investigate the processes of STX uptake and translocation to ribosomes by a route which differs from that of the native toxin. Elucidation of the mechanism of action used by the StxA-CD4 fusion proteins may facilitate the future development of toxin chimeras with therapeutic applications.
